Press releases
- Newron Presents 2023 Financial Results and Provides 2024 Outlook
- Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
- Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)
Key statistics
On Thursday, Newron Pharmaceuticals SpA (NP5:DEU) closed at 7.90, 106.81% above the 52 week low of 3.82 set on Jun 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.65 |
---|---|
High | 8.20 |
Low | 7.65 |
Bid | 7.95 |
Offer | 8.00 |
Previous close | 7.80 |
Average volume | 16.05k |
---|---|
Shares outstanding | 18.63m |
Free float | 17.16m |
P/E (TTM) | -- |
Market cap | 144.58m CHF |
EPS (TTM) | -0.8842 CHF |
Data delayed at least 15 minutes, as of Mar 28 2024 20:50 BST.
More ▼